Home ›
Ovarian Cancer Trials ›
NCT05236686
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
Trial Details
NCT ID NCT05236686
Phase NA
Sponsor Shanghai Gynecologic Oncology Group
Status RECRUITING
Cancer Type Ovarian Cancer
Interventions Hepato-celiac lymphadenectomy
Locations (sample) Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
Age ≥18 years to ≤ 75 years. Pathologic confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (EOC, PPC, FTC) or platinum s… Hepato-celiac lymph nodes metastases diagnosed by imaging before surgery and enlarged palpable lymph nodes by surgical findings Assessed by the experienced surgeons, complete resection is feasible according to preoperative evaluation
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Ovarian Cancer Trials on Trialify →